Member of Scientific Advisory Board
phammaceutical science
AsclepiX Therapeutics
United States of America
Peter Campochiaro, M.D. is the George S. & Dolores Doré Eccles Professor of Ophthalmology and Neuroscience at the Johns Hopkins University School of Medicine. He serves as a Member of Scientific Advisory Board of CoMentis, Inc. (alternate name Athenagen Inc) and as a Member of the Scientific Advisory Board of Potentia Pharmaceuticals, Inc. Dr. Campochiaro served as a Member of Scientific Advisory Board of Eyegate Pharmaceuticals, Inc.
Dr. Campochiaro has strong expertise with retinal diseases including animal models for NVAMD and significant experience with clinical trials testing NVAMD agents such as Lucentis (Genentech/Roche) and Eylea (Regeneron). Dr. Campochiaro has published over 300 scientific papers in these research areas.